In the past 3 years, targets for therapeutics and strategies for prevention against coronavirus disease 2019 (COVID-19) were identified and developed based on the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of infection. Therapeutics for COVID-19 regarding disease time course, symptoms and interventions, different stages of the SARS-CoV-2 lifecycle, and COVID-19-associated immunomodulatory effects were discussed by Toussi et al. 1 Drug treatment of COVID-19 infection regarding mild-to-moderate COVID-19 disease in the outpatient setting, patients hospitalized with mildto-moderate disease, patients hospitalized with the severe and critical disease were recently reviewed by Lui and Guaraldi. 2 EDITO RIA L